Trial Profile
A Double Blind, Within Subject, Placebo Controlled Randomised Trial to Investigate the Scar Improvement Efficacy of a Single Intradermal Application of RN1001 (Avotermin) in Female Subjects Undergoing Bilateral Breast Augmentation
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 21 May 2014
Price :
$35
*
At a glance
- Drugs Avotermin (Primary)
- Indications Scars
- Focus Therapeutic Use
- Sponsors Renovo
- 21 May 2014 New trial record